Cancer Diagnostics – Multimedia

In this episode we speak with Tom Charlesworth and discuss how the 6-base genome can improve the understanding tumour biology from liquid biopsy.

Learn what truly matters in cfDNA quality analysis. The Agilent Cell-free ScreenTape assay for the Agilent TapeStation systems uses the %cfDNA score to characterize HMW contamination and provides the actual cfDNA concentration.

Isolating single cells is crucial in various research fields such as rare-cell analysis, biologics discovery and stem cell research. However, the process of identifying and isolating productive single cells remains a significant challenge, partly due to resource-intensive and often ineffective techniques like limiting dilution.

This infographic takes a look at some of the benefits that liquid biopsies can offer and explores examples of recent developments in this field.

Liquid biopsy for profiling of cell free DNA (cfDNA) in blood holds huge promise to transform how we experience and manage cancer by early detection and identification of residual disease and subtype. However, a standard blood draw yields an average of only 10 ng of cfDNA, of which DNA derived from the tumor is a small minority.

In this episode we discuss how the combination of both genetic and epigenetic information within a single DNA sample can provide key insights on the dynamic interactions that are occurring, offering significant advantages in many research areas.

In this Teach me in 10 episode we will explore how simultaneous sequencing of genetic and epigenetic bases in cfDNA allows for early cancer detection.

In this video, Dr. Charles Rosser, a board-certified urologist discusses the development of Oncuria for the early detection of bladder cancer.

Analyzing nucleic acids provides insights into a variety of biological processes. However, the quality of your isolated DNA or RNA has a direct impact on the success of your genomic techniques and applications.

Ambient ionization mass spectrometry techniques that enable direct, gentle, and rapid analysis of samples offer exciting opportunities to provide clinicians with rich molecular data to enhance decision-making. Here, an overview of several ongoing clinical projects in the Eberlin laboratory related to the development of a handheld MS-based device, the MasSpec Pen technology, for improving patient care will be discussed. In particular, I will describe results centered around our efforts in employing the MasSpec Pen for intraoperative tissue analysis and cancer detection, identification of infectious microorganisms, and detection of drugs of abuse.